Navigation Links
Eosinophils, Sputum

ProductsEosinophils, Sputum
Company ARUP Laboratories
Item Eosinophils, Sputum
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Absolute Eosinophils, Nasal
2. Absolute Eosinophils, Sputum
3. Eosinophils, Nasal
4. Sputum Cytology
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
Medicine Products:
(Date:11/26/2009)...tions announces a highly effective and unconventio...g to make an economic recovery. , ... the type of challenge that could send ailing holi...David Benton, business growth expert and author of... The Rfactor Intensive . “Fear is one of ...
(Date:11/25/2009)...e-FirstCall/-- OnyxPharmaceuticals,Inc.(Nasdaq: O...oreventsinDecember: ,, ASHBriefing ,, ...cipalinvestigatorswilldiscussdatapresentationssurr...lemyeloma,asfeaturedatthe51stAmericanSocietyofHema...LA.Theteleconferencewillbeginat9:00a.m.CT/10:00a.m...
(Date:11/25/2009)...-USNewswire/--AnarticlebyJanetWoodcock,M.D.,direct...led"ADifficultBalance-PainManagement,DrugSafety,an...ndJournalofMedicine. ,, (Logo: http://www.newsc...article,WoodcockdiscussesFDAeffortstostrikeabalanc...managingtherisksposedbyvariousanalgesics.Asexample...
(Date:11/25/2009)... who were treated with cisplatin-based chemotherap...ical side effects and Raynaud-like phenomena, than...ding to a new study published online November 25 i..., Marianne Brydy, M.D., of the Department of Onc...orway, and colleagues conducted a cross-sectional ...
(Date:11/25/2009)...o draw definite conclusions, experts say, , ...iabetic patients with blocked coronary arteries, t...e year whether patients undergo bypass surgery or ...ort. , Bypass surgery has been the standard tre...disease. However, less invasive approaches such as...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3
...common, naturally occurring virus that attacks can...ls is being studied as a possible treatment for ma... called gliomas. Researchers at Cedars-Sinai Medic...the virus in its natural state. It commonly infect...
...and African plants are being used by Queensland re...o treat chronic pain. , Professor David Craik an...r Bioscience have received $218,275 from the Natio...he molecule they have developed have shown that it...
...mon and severe symptom reported by middle-aged wom... into the menopause, according to a study in the A...sing. , Researchers at the University of Arizona ...s. Their average age was 49 and they had all exper...
...Xinhua-PRNewswire-FirstCall/ --,China RuiTai Inter...RUI),(,China RuiTai, or ,the Company,), a leading ...ts in the People,s Republic of China (,PRC,),today...n -- Gross profit increased 33.4% to $11.9 millio...
...rience in both healthcare and human ...Precyse Solutions, the leader in,driving peak perf...,departments, today announced the appointment of K...f Human Resources,and Administration. With over 25...
...verwhelmingly want their next President to focus m...ng universal healthcare, and stemming the,outsourc...igrants to live,and work in the U.S., according to...ing of 1,125 working,Americans between April 4 and...
Other Medicine News:Health News:Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells 2Health News:Cone snails and plants used to develop oral drug for pain 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 2Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 4Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 5Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 6Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 7Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 8Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 9Health News:Precyse Solutions Appoints Karen Heisler as New Corporate Vice President, Human Resources 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 3
(Date:11/25/2009)...therlandsandJOHANNESBURG,November25/PRNewswire/--,...overyannouncedtoday,thattheyhavesignedacollaborati... , Pyxis,sworldclasscomputationalchemistryand...ervicedivisiontoprovidemedicinaland,syntheticchemi...nationalclientnetwork.iThembaPharmaceuticalsandPyx...
(Date:11/24/2009)...Nov.24/PRNewswire/-- ,, WHAT:RomHoubens,aBelgia...toaccident,wasactuallyfullyconsciousandawakeduring...nt.TheDynaVoxEyeMaxwasfeaturedinthesegmenttoillust...nscanunlockcommunication. ,, WHEN:GoodMorningAm...w.dynavoxtech.com ,, WHO:RomHoubenswasaneng...
(Date:11/24/2009)...v.24/PRNewswire-FirstCall/--AnadysPharmaceuticals,...atthe21stAnnualPiperJaffrayHealthcareConferenceonT...econferenceisbeingheldatTheNewYorkPalaceHotel.Stev...Anadys,willprovideanoverviewofAnadysanditsclinical...oratepresentationwillbesimultaneouslywebcastandcan...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 1Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 2Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 3Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 4Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 5WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 1WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 2WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 3Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 1Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 2Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 3